Home > Blog

Blog | Veristat, The Science-First CRO

Gain the latest insights and trends in clinical trials, patient recruitment, data analysis, adaptive design, regulatory submissions and approvals.

Sign Up Today

3 min read

Monthly FDA Guidance and Regulatory News Review - May 2025

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...

READ MORE

2 min read

Staying Ahead of Regulatory Change: CMC Strategies for Cell and Gene Therapy Development

The regulatory landscape for cell and gene therapies (CGTs) is shifting fast. From increased scrutiny on Chemistry, Manufacturing, and Controls (CMC) to operational challenges at the U.S. Food and Drug Administration (FDA), sponsors must be prepared to...

READ MORE

4 min read

Marketing Application Publishing Best Practices

Effectively managing the publishing of documents required for a marketing application submission can help accelerate the time it takes to bring your product to market. 

READ MORE

5 min read

Multi-Regional Clinical Trials: Key Recommendations for a Global Clinical Development Program

The FDA recently released a draft guidance on the use of multi-regional clinical trials (MRCTs) in oncology research. A well-planned MRCT can be an efficient approach to the global clinical development of a novel product, allowing for access to a wider...

READ MORE

3 min read

Top 3 Tips for Choosing the Right Oncology CRO

The decision to partner with a Clinical Research Organization (CRO) is never taken lightly—especially in oncology. With high complexity, accelerated timelines, and evolving regulatory expectations, the stakes in oncology drug development are uniquely...

READ MORE

3 min read

Ensuring Patient Safety and Data Integrity with Veristat’s DMC Expertise

Data Monitoring Committees (DMCs) play a vital role in clinical trials by providing independent oversight to ensure patient safety, maintain scientific validity, and uphold data integrity. With clinical trials becoming increasingly complex, especially...

READ MORE

3 min read

FDA Delays Push Biotech Companies to Rethink U.S. Drug Development Strategy

A growing number of biotech firms are questioning their long-standing strategy of initiating clinical trials in the U.S. first, as the Food and Drug Administration (FDA) continues to struggle with internal upheaval and reductions in staffing, leading to...

READ MORE

3 min read

Bayesian Study Designs in Early-Phase Oncology Trials

The development of innovative oncology therapies has evolved dramatically, moving beyond traditional chemotherapies to include immunotherapies, targeted agents, radiotherapies, and cell and gene therapies. As these new modalities emerge, the limitations...

READ MORE

3 min read

Monthly FDA Guidance and Regulatory News Review - April 2025

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...

READ MORE

1 min read

Staying the Course: What FDA Staffing Reductions Mean for Drug Development Today

The U.S. Food and Drug Administration (FDA) is undergoing significant change. Recent announcements have highlighted budget constraints, hiring freezes, and reductions in force (RIFs) across federal health agencies, including the FDA. These shifts have...

READ MORE